Psychotic Disorders Program
Welcome to the IU Psychotic Disorders' webpage! The Psychotic Disorders Program focuses on education, research, and treatment that will lead to improvement in the lives of individuals affected by psychotic disorders. IUPDP has two clinics: the IU Psychotic Disoders Clinic and the Prevention and Recovery Center for Early Psychosis (PARC).
Prodromal schizophrenia research is now an international movement, but any discussion of this field must acknowledge the seminal contributions of our Australian colleagues, Patrick McGorry and Allison Yung . McGorry and Yung catalyzed this field in the mid-1990s by proposing the first objective criteria that described the at-risk mental state in prospective terms. Since then, McGorry and Yung have pioneered a variety of assessment, treatment, and service delivery mechanisms for persons in the earliest stages of psychotic illness.
Their work has excited tremendous interest world-wide. What started as a single research program in Australia has become an international movement, with at least 35 prodromal research centers distributed across five continents.
In the News
Indiana CTSI to assist NCATS-sponsored drug study
July 9, 2013
The Indiana CTSI will provide support to one of the only nine researcher teams selected to participate in a new program from the National Institutes of Health that aims to identify new uses for drugs that have undergone significant research and development by industry, including safety testing in humans.
Alan Breier, M.D., Association for the Advancement of Mental Health Research and Education, Inc. and Indiana University Psychiatry Associates Professor of Psychiatry at the IU School of Medicine, will receive $1.2 million from the National Center for Advancing Translational Sciences (NCATS) for the first year of a $3.8 million three-year grant.
The Indiana CTSI will support the project through data management, sample processing and the study design. NCATS is the same center that oversees the award program supports the Indiana CTSI.Dr. Breier received the highly competitive grant from the Discovering New Therapeutic Uses for Existing Molecules program to study estrogen as a treatment for schizophrenia using an unreleased drug developed by Eli Lilly and Co.
See an informational clip from 60 Minutes about the lives of those diagnosed with Schizophrenia:
Dr. Jen Vohs' manuscript entitled "Metacognitive Mastery and Intrinsic Motivation in Schizophrenia" has been formally accepted for publication in The Journal of Nervous and Mental Disease! Manuscript scheduled to be made publicly available around March 2014.
Dr. Mike Francis and Dr. Jen Vohs received NARSAD Young Investigator Grant award letters! The two-year grant project period will be January 15, 2014 - January 14, 2016.
Dr. Vohs's Grant Title: An Integrated Metacognitive Approach to Improve
Insight and Outcomes in Early Psychosis
Dr. Francis's Grant Title: Cortical Activation and Cognitive Performance During Repetitive Transcranial Magnetic Stimulation in First Episode Psychosis: A Pilot Study
A big CONGRATULATIONS to our very own DR. MIKE FRANCIS on receiving 4 awards at the Resident Graduation Ceremony!
William Fisher Award - Given to a graduating resident for excellence in clinical and academic performance. This award is selected by the Residency Training Committee.
Clare Assue Award - Given to the graduating resident who contributed the most to the education of other residents. This award is selected by residents currently in the program.
IPS Roeske Research Award -Given at graduation by the Indiana Psychiatric Society for excellence in psychiatric research. Selected by the Psychiatry Resident Research Committee.
Joseph Hingtgen Scholarly Award - Given at graduation to the resident with the best scholarly paper. Selected by the Psychiatry Resident Research Committee.
Free and anonymous Mental Health screening through IUPUI Counseling and Psychological Services!
NIH to fund collaborations with industry to identify new uses for existing compounds:
Each award recipient will test a selected compound for its effectiveness against a previously unexplored disease or condition. The eight disease areas represented are alcohol dependence, Alzheimer’s disease, calcific aortic valve stenosis, nicotine dependence, peripheral artery disease, schizophrenia, and two rare diseases: Duchenne muscular dystrophy and the progressive lung disease lymphangioleiomyomatosis.
For more details about each project, please visit http://www.ncats.nih.gov/therapeutics-projects.html.
The schziophrenia project, award recipient principal investigators and industry partners are:
The efficacy and safety of a selective estrogen receptor beta agonist (LY500307)
Academic Partner: Alan Breier, M.D., Indiana University, Indianapolis
Industry Partner: Eli Lilly and Company
For more information, click here: http://www.nih.gov/news/health/jun2013/ncats-18.htm